Skip to main content
SpringerLink
Log in

Myasthenia Gravis

Options and Timing of Immunomodulatory Treatment

  • Therapy in Practice
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The autoimmune pathogenesis of myasthenia gravis is relatively well understood. The current options for treatment of this disease are acute and long term immunotherapies, acetylcholinesterase inhibitors and thymectomy. Many factors influence the timing of initiation of immunomodulatory therapy in myasthenia gravis and both disease factors, such as stage and severity, and patient factors, such as age, pregnancy and intercurrent illness, must be considered. Decisions regarding the choice of therapy can be difficult because of the limited number of randomised controlled trials that have been performed in myasthenic patients. In general, acetylcholinesterase inhibitors alone are used only in mild ocular disease, and in the majority of other patients immunomodulatory therapy is begun early. Corticosteroids are the most commonly used initial therapy, followed by azathioprine. In refractory cases, the available options include immunosuppressants such as cyclosporin, mycophenolate mofetil and cyclophosphamide. Plasmapheresis and intravenous immunoglobulin are important in the treatment of acute exacerbations and myasthenic crisis and in the perioperative setting. Despite many years of experience, the role of thymectomy in improving long term outcome in nonthymomatous myasthenia gravis remains controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330(25): 1797–810

    Article  CAS  PubMed  Google Scholar 

  2. Dalakas MC. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Ann Neurol 1995; 37(Suppl. 1): S2–S13

    Article  PubMed  Google Scholar 

  3. Lewis RA, Selwa JF, Lisak RP Myasthenia gravis: immunological mechanisms and immunotherapy. Ann Neurol 1995; 37(Suppl. 1):S51–S62

    Article  PubMed  Google Scholar 

  4. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000; 23: 453–77

    Article  CAS  PubMed  Google Scholar 

  5. Horton RM, Manfredi AA, Conti-Tronconi BM. The ‘embryonic’ gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle. Neurology 1993; 43: 983–6

    Article  CAS  PubMed  Google Scholar 

  6. Butler J, Pitz R, Czep M, et al. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998; 43: 458–64

    Article  Google Scholar 

  7. Romi F, Skeie GO, Aarli JA, et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000; 247: 369–75

    Article  CAS  PubMed  Google Scholar 

  8. Levinson AI, Wheatley LM. The thymus and the pathogenesis of myasthenia gravis. Clin Immunol Immunopathol 1996; 78(1): 1–5

    Article  CAS  PubMed  Google Scholar 

  9. Lara PN. Malignant thymoma: current status and future directions. Cancer Treat Rev 2000; 26: 127–31

    Article  PubMed  Google Scholar 

  10. Nicolaou S, Muller NL, Li DK, et al. Thymus in myasthenia gravis: comparison of CT and pathologic findings and clinical outcome after thymectomy. Radiology 1996; 201: 471–4

    CAS  PubMed  Google Scholar 

  11. Perlo VP, Arnason B, Castleman B. The thymus gland in elderly patients with myasthenia gravis. Neurology 1975; 25: 294–5

    Article  CAS  PubMed  Google Scholar 

  12. Wittbrodt ET. Drugs and myasthenia gravis: an update. Arch Intern Med 1997; 157: 399–408

    Article  CAS  PubMed  Google Scholar 

  13. Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997; 244: 112–8

    Article  CAS  PubMed  Google Scholar 

  14. Camera L, Brunetti A, Romano M, et al. Morphological imaging of thymic disorders. Ann Med 1999; 31(Suppl. 2): 57–62

    PubMed  Google Scholar 

  15. Donaldson DH, Ansher M, Horan S, et al. The relationship of age to outcome in myasthenia gravis. Neurology 1990; 40: 786–90

    Article  CAS  PubMed  Google Scholar 

  16. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981; 371: 652–69

    Article  Google Scholar 

  17. Howard FM, Duane DD, Lambert EH, et al. Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci 1976; 274: 596–607

    Article  PubMed  Google Scholar 

  18. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15:291–8

    Article  CAS  PubMed  Google Scholar 

  19. Sghirlanzoni A, Peluchetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984; 34: 170–4

    Article  CAS  PubMed  Google Scholar 

  20. Gajdos P, Elkharrat D, Chevret S, et al. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 1993; 56: 1157–63

    Article  Google Scholar 

  21. Bromberg MB, Wald JJ, Forshew DA, et al. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. JNeurol Sci 1997; 150: 59–62

    Article  CAS  Google Scholar 

  22. Palace J, Newsom-Davis J, Lecky B, et al. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50: 1778–83

    Article  CAS  PubMed  Google Scholar 

  23. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998; 97: 370–3

    Article  CAS  PubMed  Google Scholar 

  24. Keesey J. A treatment algorithm for autoimmune myasthenia in adults. Ann N Y Acad Sci 1998; 841: 753–68

    Article  CAS  PubMed  Google Scholar 

  25. Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235: 449–53

    Article  CAS  PubMed  Google Scholar 

  26. Hohlfeld R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258–61

    Article  CAS  PubMed  Google Scholar 

  27. Tindall RSA, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316: 719–24

    Article  CAS  PubMed  Google Scholar 

  28. Tindall RSA, Phillips JT, Rollins JA, et al. A clinical trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 539–51

    Article  CAS  PubMed  Google Scholar 

  29. Schalke BCG, Kappos L, Rohrbach E, et al. Ciclosporin A vs azathioprine in the treatment of myasthenia gravis: final results of a randomized, controlled double-blind clinical trial. Neurology 1988; 38(SI): 135

    Google Scholar 

  30. Ciafoloni E, Nikhar NK, Massey JM, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55: 448–50

    Article  Google Scholar 

  31. Perez MC, Buot WL, Mercado-Danguilan C, et al. Stable remission in myasthenia gravis. Neurology 1981; 31: 32–8

    Article  CAS  PubMed  Google Scholar 

  32. Niakan E, Harati Y, Rolak LA. Immunosuppressive drug therapy in myasthenia gravis. Arch Neurol 1986; 43: 155–6

    Article  CAS  PubMed  Google Scholar 

  33. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998; 51(3): 912–3

    Article  CAS  PubMed  Google Scholar 

  34. Merriglioni MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000; 23: 1287–9

    Article  Google Scholar 

  35. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994; 35: 260–8

    Article  CAS  PubMed  Google Scholar 

  36. Gajdos P, Chevret S, Clair B, et al. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998; 841: 720–6

    Article  CAS  PubMed  Google Scholar 

  37. Yeh J-H, Chiu H-C. Plasmapheresis in myasthenia gravis: a comparative study of daily versus alternately daily schedule. Acta Neurol Scand 1999; 99(3): 147–51

    Article  CAS  PubMed  Google Scholar 

  38. Berta E, Confalonieri P, Simoncini O, et al. Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis. Int J Artif Organs 1994; 17: 603–8

    CAS  PubMed  Google Scholar 

  39. Grob D, Simpson D, Mitsumoto H, et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45: 338–44

    Article  CAS  PubMed  Google Scholar 

  40. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789–96

    Article  CAS  PubMed  Google Scholar 

  41. Qureshi AI, Choudry MA, Akbar MS. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52: 629–32

    Article  CAS  PubMed  Google Scholar 

  42. Howard JF. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998; 51(S5): S30–S6

    Article  PubMed  Google Scholar 

  43. Christadoss P, Dauphinee MJ. Immunotherapy for myasthenia gravis: a murine model. J Immunol 1986; 136: 2437–40

    CAS  PubMed  Google Scholar 

  44. Herzog C, Walker W, Muller P, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. J Autoimmunity 1989; 2: 627–42

    Article  CAS  Google Scholar 

  45. Ahlberg R, Yi Q, Pirskanen R, et al. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody. Ann NY Acad Sci 1998; 841: 552–5

    Google Scholar 

  46. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7–15

    Article  CAS  PubMed  Google Scholar 

  47. Soliven BC, Lange DJ, Penn AS, et al. Seronegative myasthenia gravis. Neurology 1988; 38: 514–7

    Article  CAS  PubMed  Google Scholar 

  48. Nakamura H, Taniguschi Y, Suzuki Y, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. JThorac Cardiovasc Surg 1996; 112: 371–5

    Article  CAS  Google Scholar 

  49. Tsuchida M, Yamato Y, Souma T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 1999; 67: 1563–7

    Article  CAS  PubMed  Google Scholar 

  50. Mann JD, Johns TR, Campa JF, et al. Long-term prednisone followed by thymectomy in myasthenia gravis. Ann N Y Acad Sci1976; 274: 608–22

    Article  CAS  PubMed  Google Scholar 

  51. Sommer N, Sigg B, Melms A, etal. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156–62

    Article  CAS  PubMed  Google Scholar 

  52. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenie crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48: 1253–60

    Article  CAS  PubMed  Google Scholar 

  53. Berrouschot J, Baumann I, Kalischewski P, et al. Therapy of myasthenic crisis. Crit Care Med 1997; 25(7): 1228–35

    Article  CAS  PubMed  Google Scholar 

  54. Antonini G, Morino S, Gragnani F, et al. Myasthenia gravis in the elderly: a hospital based study. Acta Neurol Scand 1996; 93: 260–2

    Article  CAS  PubMed  Google Scholar 

  55. Batocchi AP, Majolini L, Evoli A. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999; 52: 447–52

    Article  CAS  PubMed  Google Scholar 

  56. Gardnerova M, Eymard B, Morel E, et al. The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn. Neurology 1997; 48: 50–4

    Article  CAS  PubMed  Google Scholar 

  57. Daskalakis GJ, Papageorgiou IS, Petrogiannis ND, et al. Myasthenia gravis and pregnancy. Eur J Obstet Gynecol Reprod Biol 2000; 89: 201–4

    Article  CAS  PubMed  Google Scholar 

  58. Andrews PI. Atreatment algorithm for autoimmune myasthenia gravis in childhood. Ann N Y Acad Sci 1998; 841: 789–802

    Article  CAS  PubMed  Google Scholar 

  59. Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 1993; 43: 977–82

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Spring was supported by a scholarship from the Nerve Research Foundation.

Author information

Authors and Affiliations

  1. Institute of Clinical Neurosciences, The University of Sydney and Royal Prince Alfred Hospital, Sydney, NSW, Australia

    Penelope J. Spring &  Judith M. Spies

Authors
  1. Penelope J. Spring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judith M. Spies
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spring, P.J., Spies, J.M. Myasthenia Gravis. BioDrugs 15, 173–183 (2001). https://doi.org/10.2165/00063030-200115030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115030-00004

Keywords

Search

Navigation